SanBio Company Limited (4592) Stock Price

SanBio is a company engaged in the research, development, manufacturing, and commercialization of cell therapy drugs in the field of regenerative medicine. The company primarily develops therapeutic drugs for central nervous system disorders, targeting diseases with high unmet medical needs such as chronic traumatic brain injury, chronic cerebral infarction, Parkinson's disease, and Alzheimer's disease.

SanBio's cell therapy drugs aim to promote the regeneration of bodily functions lost due to disease or injury. This is expected to facilitate recovery of motor function, sensory function, and cognitive function. Specific products include SB623 and SB618, which are being developed as therapeutic drugs for different diseases.

SanBio's business model involves acquiring technology from research institutions such as universities and generating revenue by licensing development and commercialization rights to pharmaceutical companies. Revenue is composed of upfront contract payments, milestone payments, development cooperation fees, royalty income, and product supply income.

SanBio has established mass production technology for allogeneic cell therapy drugs and retains product supply rights. This enables the company to generate income from product supply fees in addition to royalty income following product commercialization.

SanBio acquires and develops intellectual property necessary for the commercialization of cell therapy drugs. In particular, patents related to SB623 have been obtained in numerous countries including the United States, and the company will continue to secure intellectual property rights.

Going forward, SanBio plans to expand into the U.S. market based on its track record in Japan. The company also intends to expand the therapeutic applications of SB623 and advance clinical trials in areas such as retinal diseases, spinal cord injury, and Parkinson's disease.

SanBio is a company engaged in the research, development, manufacturing, and commercialization of cell therapy drugs in the field of regenerative medicine. The company's corporate mission is to "provide value to patients and stakeholders through the development of regenerative medicine," with the goal of becoming a global leader. In particular, the company aims to contribute to improving the quality of life for patients with unmet medical needs.

SanBio's growth strategy consists of three pillars: "restart of U.S. operations," "re-challenge in stroke treatment," and "establishing Japan as the mother base." Through these initiatives, maximizing the potential of SB623 while pursuing global leadership in regenerative medicine is the top priority. The company is rapidly advancing all processes from research and development through post-market manufacturing and sales operations.

In the medium to long term, establishing infrastructure for the commercialization of Aucugo® is the highest priority. SB623 is expected to expand its applications beyond chronic traumatic brain injury to include stroke and spinal cord injury. The company is also considering geographic expansion into Europe and Asia. Development of new cell-based therapeutics is also underway to maximize corporate value.

As the regenerative medicine industry advances toward commercialization, SanBio is pursuing global manufacturing and sales of SB623. The company aims to obtain manufacturing and marketing approval for Aucugo® and begin shipments, while building manufacturing, logistics, and sales infrastructure. These efforts will ensure stable supply and appropriate use, driving further market expansion.

Advancing research and development is also a critical priority. The company aims to restart clinical trials of Aucugo® in the United States and advance its chronic stroke program. Data collection for clinical trial initiation is underway across multiple programs, including those beyond SB623. Fundraising and talent acquisition are also important elements of the company's strategy.